摘要
目的 探讨替加环素联合美罗培南治疗肺癌合并重症肺部感染患者的临床疗效.方法 依据治疗方案的不同将80例肺癌合并重症肺部感染患者分为观察组(n=42,给予美罗培南联合替加环素治疗)和对照组(n=38,给予美罗培南治疗).比较两组患者的临床疗效、临床症状持续时间、肺功能指标[动脉血氧分压(PaO2)、动脉血二氧化碳分压(PaCO2)、用力肺活量(FVC)、第一秒用力呼气容积(FEV1)]、炎性因子水平[C反应蛋白(CRP)、白细胞介素-6(IL-6)、降钙素原(PCT)]、细菌清除率及不良反应发生情况.结果 治疗后,观察组患者的治疗总有效率为92.86%,高于对照组患者的78.95%,差异有统计学意义(P﹤0.05).观察组患者的发热持续时间、咳嗽咳痰持续时间、呼吸困难持续时间、胸痛胸闷持续时间、肺湿啰音持续时间均明显短于对照组,差异均有统计学意义(P﹤0.01).治疗后,观察组患者PaO2、FVC、FEV1均高于对照组,CRP、IL-6、PCT水平和PaCO2均低于对照组,差异均有统计学意义(P﹤0.05).治疗后,观察组患者的细菌清除率为92.86%,高于对照组患者的76.32%,差异均有统计学意义(P﹤0.05).观察组患者的不良反应总发生率为28.57%,与对照组患者的34.21%比较,差异无统计学意义(P﹥0.05).结论 替加环素联合美罗培南治疗肺癌合并重症肺部感染患者的临床疗效显著,可改善患者的肺功能指标,减轻炎性反应,提高细菌清除率,且安全性良好.
Abstract
Objective To evaluate the clinical efficacy of tigecycline combined with meropenem in the treatment of lung cancer patients complicated with severe pulmonary infection.Method According to different treatment methods,80 patients with lung cancer complicated with severe pulmonary infection were divided into observation group(n=42,treated with meropenem combined with tigecycline)and control group(n=38,treated with meropenem).The clinical effi-cacy,duration of clinical symptoms,pulmonary function indicators[arterial partial pressure of oxygen(PaO2),arterial par-tial pressure of carbon dioxide(PaCO2),forced vital capacity(FVC),forced expiratory volume in one second(FEV1)],in-flammatory factors[C-reactive protein(CRP),interleukin-6(IL-6),procalcitonin(PCT)],bacterial clearance rate,and in-cidence of adverse reactions were compared between the two groups.Result After treatment,the total effective rate in observation group was 92.86%,which was higher than 78.95%in control group,and the difference was statistically signif-icant(P<0.05).The duration of fever,cough and sputum,dyspnea,chest pain and tightness,and lung moist rales in obser-vation group were significantly shorter than those in control group,and the differences were statistically significant(P<0.01).After treatment,the levels of PaO2,FVC,and FEV1 in observation group were higher than those in control group,while the levels of CRP,IL-6,PCT,and PaCO2 were lower than those in control group,and the differences were statistical-ly significant(P<0.05).After treatment,the bacterial clearance rate in observation group was 92.86%,which was higher than 76.32%in control group,and the difference was statistically significant(P<0.05).The total incidence of adverse reac-tions in observation group was 28.57%,which was not significantly different with 34.21%in control group(P>0.05).Conclusion The clinical efficacy of tigecycline combined with meropenem in the treatment of lung cancer patients com-plicated with severe pulmonary infection is significant,which can improve lung function indicators,reduce inflammatory reactions,increase bacterial clearance rate,and has good safety.
维普
万方数据